{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:04:25Z","timestamp":1782968665118,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"crossref","award":["13\/RC\/2073"],"award-info":[{"award-number":["13\/RC\/2073"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Nebulised unfractionated heparin may attenuate COVID-19 ARDS by reducing pulmonary microvascular thrombosis, blocking SARS-CoV-2 entry into cells, and decreasing lung inflammation. COVID-19 patients with a raised <jats:sc>d<\/jats:sc>-dimer have areas of pulmonary hypoperfusion on CT perfusion scans of the lung and have increased mortality risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a phase Ib\/IIa open-label multi-centre, randomised controlled trial. The study was designed to evaluate whether nebulised unfractionated heparin decreased <jats:sc>d<\/jats:sc>-dimer concentrations, with safety as a co-primary outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty patients were recruited, with 20 patients into each group. Mean age was 56.6 (SD 11.5) in the heparin group and 51.3 (SD 14.7) in the standard care group, while 60% of participants were male. There was no change in <jats:sc>d<\/jats:sc>-dimers from baseline to day 10 (heparin group mean change \u2212\u00a0316.5, [SD 1840.3] and control group mean change \u2212\u00a0321.7 [SD 3589.4]; <jats:italic>p<\/jats:italic>\u2009=\u20090.996). Fourteen patients suffered at least one serious adverse event, 9 patients the Heparin group and 5 in the control group. Eight patients had one or more bleeding events, 5 in the heparin group and 3 in the control group, but were no cases of pulmonary bleeding, of severe haemorrhage or of heparin-induced thrombocytopenia. Patients receiving heparin therapy had lower PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> ratios, increased oxygenation indices, and decreased ROX index profiles, up to day 10. The time to separation from respiratory support, and the time to ICU or hospital discharge was similar in both groups. There were 3 deaths in the Heparin group and 2 in the control group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Nebulised unfractionated heparin was safe and well tolerated, but did not reduce <jats:sc>d<\/jats:sc>-dimer concentrations, and worsened oxygenation indices in patients with COVID-19 ARDS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40635-025-00727-x","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:52:06Z","timestamp":1738954326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Can nebulised heparin reduce acute lung injury in patients with SARS\u2011CoV\u20112 requiring advanced respiratory support in Ireland: the CHARTER\u2011Ireland phase Ib\/IIa, randomised, parallel-group, open-label study"],"prefix":"10.1186","volume":"13","author":[{"given":"David","family":"Cosgrave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bairbre","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Robert","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraig","family":"Calpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Kernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez\u2011Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Cody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"McGeary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van Haren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-9573","authenticated-orcid":false,"given":"John G.","family":"Laffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"727_CR1","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/cc6894","volume":"12","author":"B Dixon","year":"2008","unstructured":"Dixon B, Santamaria JD, Campbell DJ (2008) A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 12:R64","journal-title":"Crit Care"},{"key":"727_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","volume":"9","author":"B Dixon","year":"2021","unstructured":"Dixon B, Smith RJ, Campbell DJ, Moran JL, Doig GS, Rechnitzer T, MacIsaac CM, Simpson N, van Haren FMP, Ghosh AN, Gupta S, Broadfield EJC, Crozier TME, French C, Santamaria JD, CHARLI Study Group (2021) Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 9:360\u2013372","journal-title":"Lancet Respir Med"},{"key":"727_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S2213-2600(20)30370-2","volume":"8","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, Laffey J, Carrafiello G, Carsana L, Rizzuto C, Zanella A, Scaravilli V, Pizzilli G, Grieco DL, Di Meglio L, de Pascale G, Lanza E, Monteduro F, Zompatori M, Filippini C, Locatelli F, Cecconi M, Fumagalli R, Nava S, Vincent JL, Antonelli M, Slutsky AS, Pesenti A, Ranieri VM, Collaborators (2020) Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med 8:1201\u20131208","journal-title":"Lancet Respir Med"},{"key":"727_CR4","doi-asserted-by":"publisher","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","volume":"319","author":"JA Hippensteel","year":"2020","unstructured":"Hippensteel JA, LaRiviere WB, Colbert JF, Langouet-Astrie CJ, Schmidt EP (2020) Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 319:L211\u2013L217","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"727_CR5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18:1094\u20131099","journal-title":"J Thromb Haemost"},{"key":"727_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844\u2013847","journal-title":"J Thromb Haemost"},{"key":"727_CR7","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.jbc.2021.101507","volume":"298","author":"G Paiardi","year":"2022","unstructured":"Paiardi G, Richter S, Oreste P, Urbinati C, Rusnati M, Wade RC (2022) The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. J Biol Chem 298:101507","journal-title":"J Biol Chem"},{"key":"727_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.05959.x","volume":"133","author":"H Hochart","year":"2006","unstructured":"Hochart H, Jenkins PV, Smith OP, White B (2006) Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 133:62\u201367","journal-title":"Br J Haematol"},{"key":"727_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","volume":"24","author":"FMP van Haren","year":"2020","unstructured":"van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D, Wilkinson T, Dixon B (2020) Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 24:454","journal-title":"Crit Care"},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s13063-022-06518-z","volume":"23","author":"JR Sheehan","year":"2022","unstructured":"Sheehan JR, Calpin P, Kernan M, Kelly C, Casey S, Murphy D, Alvarez-Iglesias A, Giacomini C, Cody C, Curley G, McGeary S, Hanley C, McNicholas B, van Haren F, Laffey JG, Cosgrave D (2022) The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial. Trials 23:774","journal-title":"Trials"},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/cc9269","volume":"14","author":"B Dixon","year":"2010","unstructured":"Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD (2010) Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 14:445","journal-title":"Crit Care"},{"key":"727_CR12","doi-asserted-by":"publisher","first-page":"R180","DOI":"10.1186\/cc9286","volume":"14","author":"B Dixon","year":"2010","unstructured":"Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ (2010) Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 14:R180","journal-title":"Crit Care"},{"key":"727_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126","journal-title":"J Thromb Haemost"},{"key":"727_CR14","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"Remap-Cap Investigators","year":"2021","unstructured":"Remap-Cap Investigators (2021) Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med 384:1491\u20131502","journal-title":"N Engl J Med"},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"102212","DOI":"10.1016\/j.pupt.2023.102212","volume":"80","author":"G DeNucci","year":"2023","unstructured":"DeNucci G, Wilkinson T, Sverdloff C, Babadopulos T, Woodcock A, Shute J, Renato Guazelli P, Gerbase LF, Mour\u00e3o PAS, Singh D, van Haren FMP, Page C (2023) Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: a randomised controlled pilot study. Pulm Pharmacol Ther 80:102212","journal-title":"Pulm Pharmacol Ther"},{"key":"727_CR16","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1111\/bcp.15212","volume":"88","author":"FMP van Haren","year":"2022","unstructured":"van Haren FMP, van Loon LM, Steins A, Smoot TL, Sas C, Staas S, Vilaseca AB, Barbera RA, Vidmar G, Beccari H, Popilevsky F, Daribayeva E, Venkatesan B, Mozes S, Postel R, Popilevski N, Webb A, Nunes Q, Laffey JG, Artigas A, Smith R, Dixon B, Richardson A, Yoon HJ, Page C (2022) Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: a multicentre case series of 98 patients. Br J Clin Pharmacol 88:2802\u20132813","journal-title":"Br J Clin Pharmacol"},{"key":"727_CR17","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1111\/bcp.15253","volume":"88","author":"FMP van Haren","year":"2022","unstructured":"van Haren FMP, Laffey JG, Artigas A, Page C, Schultz MJ, Cosgrave D, McNicholas B, Smoot TL, Nunes Q, Richardson A, Yoon HJ, van Loon LM, Ghosh A, Said S, Panwar R, Smith R, Santamaria JD, Dixon B (2022) Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. Br J Clin Pharmacol 88:3272\u20133287","journal-title":"Br J Clin Pharmacol"},{"key":"727_CR18","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1111\/bcp.14714","volume":"87","author":"FMP van Haren","year":"2021","unstructured":"van Haren FMP, Richardson A, Yoon HJ, Artigas A, Laffey JG, Dixon B, Smith R, Vilaseca AB, Barbera RA, Ismail TI, Mahrous RS, Badr M, De Nucci G, Sverdloff C, van Loon LM, Camprubi-Rimblas M, Cosgrave DW, Smoot TL, Staas S, Sann K, Sas C, Belani A, Hillman C, Shute J, Carroll M, Wilkinson T, Carroll M, Singh D, Page C (2021) INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. Br J Clin Pharmacol 87:3075\u20133091","journal-title":"Br J Clin Pharmacol"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-025-00727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-025-00727-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-025-00727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:52:09Z","timestamp":1738954329000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-025-00727-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1186\/s40635-025-00727-x","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the National Research Ethics Committee (NREC) in Ireland, approval number 20-NREC-COV-104. Regulatory approval for the study was obtained from the Health Products Regulatory Authority, approval number CT0900\/650\/001 Heparin Sodium. Written informed consent or assent was obtained from all patients prior to inclusion in the trial for collection, storage, analysis and dissemination of the results of the trial. The trial was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent or assent was obtained from all patients prior to inclusion in the trial for publication and dissemination of the results of the trial.Availability of data and materials: The datasets used and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JL is a senior editor of Intensive Care Medicine Experimental. JL has received consulting fees from Cellenkos Inc. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}